Loading...
Immunotech Biopharm Ltd
6978.HK•HKSE
Healthcare
Biotechnology
HK$4.01
HK$-0.16(-3.84%)
Immunotech Biopharm Ltd (6978.HK) AI-Powered Stock Analysis
See how Immunotech Biopharm Ltd scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerImmunotech Biopharm Ltd (6978.HK) Stock Overall Grade
Immunotech Biopharm Ltd’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Immunotech Biopharm Ltd's overall stock rating.
Forecast
C+Score
55/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
51/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Immunotech Biopharm Ltd (6978.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Immunotech Biopharm Ltd stock grade, including financials, comparisons, and forecasts.